Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B

by | Jun 29, 2026 | Clinical Trials | 0 comments

​ Conditions: HBV Infection

Interventions: Drug: TVAX-028; Other: Adjuvant

Sponsors: Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Not yet recruiting Conditions: HBV Infection
Interventions: Drug: TVAX-028; Other: Adjuvant
Sponsors: Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *